Introduction
The p53 tumor suppressor is a key modulator of tumorigenesis and a central target in cancer therapy (1) . Commonly referred to as a master regulator, p53 has the ability to initiate a variety of cellular responses upon activation, including cell cycle arrest, senescence, apoptosis, and autophagy (2) . In cancers retaining wild-type (wt) p53, protein function is limited by MDM2, the primary negative regulator of p53. Inhibition of p53 by MDM2 is achieved via suppression of transcriptional activity, promotion of cytoplasmic export, and/or protein degradation (3) .
Given the pivotal role of p53 in tumor suppression, several therapeutic strategies to activate p53 by disrupting the negative control by MDM2 have been investigated. Many approaches have been described, including antisense oligonucleotides against MDM2, smallmolecule inhibitors of MDM2 ubiquitin ligase activity, and small-molecule MDM2 inhibitors, which hinder p53-MDM2 interaction (4) . In 2004, the identification of Nutlin-3 as the first small-molecule inhibitor of MDM2 spurred interest in this approach, which led to the development of several analogous compounds (5) . Recent studies have demonstrated the antitumor capacity of small-molecule MDM2 inhibitors both in vitro and in vivo, and several of these compounds have advanced to clinical trials (1, 6) .
AMG 232 is an inhibitor of MDM2 that is designed to target the p53 binding site of MDM2 which covers amino acids 17 to 111 in the N-terminus (7, 8) (Supplementary Fig. 1A ).
AMG 232 robustly activates p53 signaling and has potent anti-tumor activity in both in vitro and in vivo models (7, 9) . Emerging evidence has linked MDM2 to the radiation-induced DNA damage repair response by a direct binding to Nbs1 that is a critical member of the Mre11-Nbs1-Rad50 repair pathway (10).
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Radiation is a core cancer treatment modality delivered to over 50% of all cancer patients during the course of their disease. Although very effective when high dose can be delivered, radiation is frequently limited by normal tissue tolerance. There is a compelling rationale to identify promising molecular targeting agents that may sensitize tumor cells to radiation (11) .
Considering the significant role of both p53 and MDM2 in the regulation of radiation response, and the activation of p53 achieved by small-molecule MDM2 inhibitors, the combination of AMG 232 and radiation may offer a valuable therapeutic approach in cancer therapy. In the current study, we evaluated the capacity of AMG 232 to augment radiation response across a variety of tumor types. In addition, we highlight the potential underlying molecular mechanisms involved in the regulation of AMG 232-mediated radiation response.
Materials and Methods
Reagents and antibodies. were stained with crystal violet and colonies consisting of 50 cells or more were scored. The surviving fraction was determined as the total number of colonies formed divided by the total number of cells seeded. Radiation survival curves were plotted after normalization for the cytotoxicity induced by control or drug alone. Cell viability was examined either by crystal violet staining or propidium iodide (PI) dye exclusion flow cytometric assay as described previously (12) . Following staining with PI (30 μg/mL) for 30 min, dead cells permeable to PI were quantified by analyzing the geometric mean fluorescence intensity (GMFI) of PI in 10,000 cells.
Quantification of mRNA expression. Relative mRNA levels of p53, p21, MDM2, FoxM1, ULK1, DRAM1 and BAX were quantified via real-time PCR (RT-qPCR) using a Bio-Rad iQ5 RT-qPCR Detection System and Power SYBR Green PCR Master Mix (Life Technologies). All reactions were performed in triplicate. The geometric mean of three reference genes (GAPDH, PGK, & TBP) was calculated and used as an endogenous control. Fold changes after treatments were normalized to a control sample at time 0. Detailed primer information for each molecule is provided in the "Supplementary Materials and Methods." 7 Flow cytometric analysis of γH2AX. Following treatments, cells were fixed in ice-cold 70% ethanol followed by rehydration for 10 min at 4°C in PBS containing 1% BSA and 0.2% Triton X-100. Cells were then stained with anti-phosho-Histone H2AX (γH2AX) (Ser139) mAb (Clone JBW301, EMD Millipore, Billerica, MA) overnight at 4°C followed by an AF488-secondary antibody for 1 h. Following centrifugation, cells were resuspended in PI solution to determine the cell cycle phase for cells with γH2AX as described previously (13) .
Senescence associated β-galactosidase detection. Cells (2x10 4 ) were plated in 6-well plates and treated with AMG 232 and/or radiation. Following 72 hrs of treatment, cells were stained for senescence-associated β-galactosidase using the Senescence Detection kit (Cell Signaling Technology, Beverly, MA).
Immunofluorescence (IF).
Cells in chamber slides were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Cells were then probed with anti-FoxM1 Ab, followed by AF488-secondary Ab. The number of nuclear FoxM1-positive cells was analyzed using Image J software.
Detection of acidic vesicular organelles (AVOs) with acridine orange staining. AVOs, as marker of autophagy, were detected by acridine orange (AO) flow cytometry as described previously (14) . To quantify the development of AVOs, cells were stained with 1 μg/mL of AO for 15 minutes and were then removed from the plate with trypsin-EDTA and collected for flow cytometric analysis.
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Apoptosis and mitochondria membrane potential. Apoptosis was detected by flow cytometry using an Annexin V/PI dual staining kit from BD Biosciences Pharmingen (San Diego, CA) as described previously (15) . Mitochondrial membrane potential was examined using JC-1 dye as described previously (16) . In healthy cells, the polarized mitochondrial membrane potential (ΔΨ) drives JC-1 uptake into the mitochondria, where JC-1 aggregates form and fluoresce red.
The loss of mitochondrial membrane potential was determined by a decreased radio of red to green fluorescence.
Tumor xenograft studies. Athymic nude mice were obtained from Harlan Bioproducts for Science (Indianapolis, IN) and the care of experimental animals was conducted in accordance with institutional guidelines. Tumor cells were injected subcutaneously into the dorsal flank of the mice. Tumor volume was monitored by direct measurement with calipers and calculated by the formula: π/6 × (large diameter) ×(small diameter) 2 . AMG 232 was administered daily via oral gavage at the specified doses and time intervals. Radiation treatment was delivered with a cabinet X-ray biological irradiator X-RAD 320 from Precision X-Ray, Inc. (North Branford, CT). For A375 xenograft, the A375 SQ2 cell line was used to achieve more uniform and reproducible tumor growth. A375 SQ2 was generated by performing two serial in vivo passages of A375 cells as described previously (17) .
Statistical analysis. Prism 5 (GraphPad Software, La Jolla, CA) was used for all statistical analyses. For clonogenic assays, the Bonferroni Multiple Comparison Test was applied. For all other experiments, the Student's t-test was used. In all results, unless otherwise indicated, the 9 data reflect at least 2 independent experiments and were reported as mean±SD. For all graphs, *p<0.05, **p<0.01, ***p<0.001
Results

AMG 232 activates p53 signaling and inhibits tumor cell proliferation
To assess the effect of AMG 232 on p53 signaling, we measured p53, MDM2 and p21 protein levels across a panel of tumor cell lines, including lung (A549, H460, H226 & H1299), melanoma (A375), breast (MCF7), colon (HCT116) and osteosarcoma (SJSA-1). All cell lines harbor wt p53 except H1299, which is p53 null. AMG 232 activated p53-p21 signaling in a dose-dependent manner in the majority of cell lines tested (Fig. 1A) . Similar to previous studies, the degree of p53 induction varied among different cell lines, likely reflecting differences in the baseline level of p53 and MDM2 as well as the optimal dose/time response to AMG 232 (9).
However, a consistent and profound induction of p21 level was observed in all cell lines tested.
Since p21 is the key indicator of p53 activity, this observation confirms the ability of AMG 232 to activate p53. AMG 232 also promoted an increase in MDM2, resulting from negative feedback auto-regulation induced by p53 activation. Importantly, the impact of AMG 232 to activate p53-p21 signaling translates well into a profound anti-proliferative effect. AMG 232 significantly reduced cell proliferation in a dose-dependent manner in all p53 wt cell lines tested, as shown in (Fig. 1C) . Similarly, radiation treatment resulted in increased expression of all three genes. However, the combined treatment of AMG 232 and radiation induced a more profound increase in p21 and MDM2 expression than single modality treatment, suggesting that the combination was more potent in activating the p53 pathway. Similar results were observed in SJSA-1 (Supplementary Fig. 1B ). Cell cycle analysis revealed that treatment with AMG 232 and radiation resulted in a significant cell cycle arrest in both G1 and G2/M phases ( Supplementary Fig. 1C ), consistent with upregulation of the cell cycle inhibitor p21. Taken together, these results suggest an interaction between AMG 232 and radiation reflecting an up-regulation of p53-p21 signaling.
AMG 232 enhances radiosensitivity of tumor cells
We investigated the effect of AMG 232 on radiosensitivity using clonogenic survival analysis. As shown in Fig. 2B ). Since a lethally irradiated cell with unrepaired DSB may continue to divide and result in the reproduction of γH2AX in daughter cells, our findings suggest that AMG 232 enhances radiosensitivity by inhibiting DSB repair, resulting in the accumulation of dying cells with unrepaired lethal DNA damage.
AMG 232 in combination with radiation induces cellular senescence
Since γH2AX is also associated with senescence by binding to dysfunctional telomeres at the end of double strands (18), we investigated the effect of AMG 232 and radiation on cell senescence by examining several senescence markers. We first examined the activity of senescence-associated β-galactosidase (SA-β-Gal) and found that combined treatment of AMG 232 and radiation resulted in a significant increase in SA-β-gal positive cells compared to treatment with either radiation or AMG 232 alone in all cell lines tested (Fig. 3A) .
Representative images of SA-β-gal staining for all cell lines tested are shown in Supplementary   Fig. 3 . Additional markers of senescence were examined to validate these findings.
FoxM1 is a critical pro-proliferative transcription factor, and its inhibition leads to cellular senescence (19) . Immunofluorescent imaging in A375 cells revealed that treatment with either AMG 232 or radiation alone at 48 hrs resulted in a minor reduction in nuclear FoxM1 staining, whereas combination treatment resulted in a significant reduction in the number of FoxM1-positive cells (Fig. 3B) . 
AMG 232 in combination with radiation induces autophagy
An interesting link between p53-mediated senescence and autophagy has been identified.
A subset of autophagy-related genes are up-regulated during senescence and apoptosis including ULK1 (unc-51 like autophagy activating kinase1) and DRAM1 (damage-regulated autophagy modulator) (20, 21) . Combined treatment with AMG 232 and radiation resulted in a synergistic increase of ULK1 and DRAM1 mRNA at 24~48hr time points, though AMG 232 alone induced a different response profile between these 2 genes (Fig. 4A) . Similar results were observed in SJSA-1 cells (Supplementary Fig. 4A ). To confirm AMG 232/radiation-induced autophagy, we examined the induction of autophagy-related acidic vesicular organelles (AVOs) (22) by acridine orange (AO) staining. AO emits red fluorescence when it enters AVOs, but stains bright green in DNA and the cytoplasm. Treatment with either AMG 232 or radiation alone produced no significant increase in cells with AVOs, as shown in the upper two quadrants (FL3-AO-red) of the 2-dimentional plots, when compared to control (Fig. 4B) . Strikingly, when cells were exposed to both AMG 232 and radiation, a robust increase of cells with AVOs was observed in all 4 cell lines tested. In H460 cells, an increase greater than five fold was observed ( 
AMG 232 in combination with radiation induces programmed cell death
Although autophagy is often induced under nutrient limiting conditions as a mechanism for maintaining cell viability, progressive autophagy can be cytotoxic and substitute for apoptosis in the induction of cell death (23, 24) . We first investigated whether the combined treatment of AMG 232 and radiation could induce programmed cell death by determining plasma membrane rupture in tumor cells. Treatment with AMG 232 or radiation alone resulted in a minimal accumulation of dead cells (Fig. 5A) we also found a significant increase in gene expression of pro-apoptotic BAX 24~48 hours after combined treatment with AMG 232 and radiation in both A375 and SJSA-1 cells (Fig. 5D) . 
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Taken together, these results suggest that the addition of AMG 232 to radiation treatment caused the induction of cellular senescence and autophagy, which ultimately resulted in cell death.
AMG 232 augments radiation response in human tumor xenografts
We next investigated the capacity of AMG 232 to augment radiation response in a variety of human tumor xenografts, representing different genetic backgrounds and tissue types including lung carcinoma, melanoma, sarcoma and colorectal carcinoma. In order to best capture the interaction between AMG 232 and radiation, doses and schedules of both treatment modalities were selected from previous studies (7, 9) for each cell line such that single agent impact on tumor growth inhibition would be modest, in the range of 10~30%. Remarkably, in every xenograft model, the combination of AMG 232 and radiation led to superior anti-tumor efficacy compared to single modality treatment as shown in Fig. 6 . After cessation of treatment, tumors in the combination treatment groups remained cytostatic and failed to regrow suggesting a senescence phenotype consistent with our previous in vitro observations. Notably, there was no significant difference in the body weight profile of mice receiving combined treatment when compared to that in radiation-or AMG 232-treated mice across our xenograft experiments (Supplementary Fig. 5) . AMG 232 appears to be well tolerated at dose levels tested when combined with radiation in these animal experiments.
To validate the functional observation in xenografts, we further examined the histology of H460 & SJSA-1 tumor specimens by IHC. By detecting a cellular proliferation marker Ki67, we found that the number of proliferating cells was significantly decreased in both H460 and SJSA-1 tumors receiving combined treatment of AMG 232 and radiation when compared to tumors receiving single modality treatment (Supplementary Fig. 6A ). These findings confirm 
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and strengthen the anti-tumor capacity of AMG 232 when combined with radiation. In concordance with reduced tumor volumes, we also found a significant reduction of vascular density in both H460 and SJSA-1 tumors receiving combined treatment of AMG 232 and radiation by staining with an endothelial cell marker, von Willebrand factor (vWF) (Supplementary Fig. 6B ). Taken together, these results suggest that AMG 232 may augment radiation response by inhibiting tumor cell proliferation and by interfering with tumor-associated angiogenesis.
Discussion
MDM2 inhibitors are a class of p53 activating agents that may be of considerable value in cancer therapeutics. Because impaired p53 function is associated with a reduced sensitivity of tumor cells to radiation, there has been considerable interest to activate p53 to promote enhanced efficacy of radiotherapy. In the current study, we present a potent MDM2 inhibitor, AMG 232, that effectively inhibits tumor proliferation and augments radiation response across a wide variety of solid tumor types expressing wt p53. Exposure of cancer cells to AMG 232 leads to activation of p53-p21 signaling and gene expression (Fig. 1) . More importantly, we identify that the combination of AMG 232 and radiation induces a synergistic effect on p53-regulated downstream cellular events involved in the response to radiation-induced DNA damage. In particular, a profound augmentation of senescence and autophagy is observed in cells following combined treatment with AMG 232 and radiation.
Premature cellular senescence has been shown to be a principal mode of cell death accounting for radiation response in cancer cells retaining p53 function (26, 27) . Therapyinduced senescence is now recognized for its contribution to the overall loss of tumor cell (28) . By examining several senescence markers, we consistently found a significant induction of senescence following combined AMG 232 and radiation treatment. This was identified by an increase in senescence-associated β-galactosidase and p21 as well as a decrease in FoxM1 expression (Fig. 3 & 1) . Interestingly, AMG 232/radiation treatment also resulted in a robust increase of γ-H2AX in G2/M phase cells 48 hrs after the initial burst observed 1 hr following treatment. In contrast, treatment with radiation or AMG 232 alone did not produce a significant impact on γ-H2AX accumulation at 48 hrs (Fig. 2B) . Since previous studies have revealed γ-H2AX as a potential senescence marker (18) , the retention of γ-H2AX in G2/Marrested cells at the later time points suggests the presence of DNA lesions with unrepairable DSBs in senescent cells. Consequently, a significant increase in cell death was observed in cells subjected to combination treatment, as indicated by either loss of mitochondrial function or rupture of cell membrane (Fig. 5) . Our results further support previous findings that reveal the retention of residual γ-H2AX, not the early γ-H2AX peak, as an indication of lethal DNA damage that induces a reduction in clonogenic survival (29, 30) .
Another interesting finding of this study is the involvement of autophagy in AMG 232-regulated radiation response. As shown in Fig. 4 , a profound increase of autophagy-related AVOs was identified in cells following combined treatment with AMG 232 and radiation.
Furthermore, autophagy-related ULK-1 and DRAM genes were significantly up-regulated in cells treated with AMG 232 and radiation. Although autophagy is often considered to be a cell survival mechanism, there is also evidence for the capacity of autophagy to mediate the antiproliferative and/or cytotoxic actions of selected anti-cancer agents (31, 32) . Furthermore, a direct crosstalk between apoptosis and autophagy has been identified that serves to reinforce cell death (33) 
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between p53 and autophagy that contributes to efficient p53-dependent apoptosis and cancer suppression (34). Nevertheless, the precise factors that determine whether p53-induced programmed cell death occurs through apoptosis or autophagy remain elusive. In some cell lines examined in our current study, such as H460 and A549, we found that autophagy was conducive to cell death when induction of apoptosis was weak or absent (Supplementary Fig. 4B ).
However, A375 cells exhibited both autophagy and apoptosis following combined treatment with AMG 232 and radiation. Additional experiments are underway to explore the molecular mechanisms and genetic backgrounds of various cell lines that may account for differential induction of programmed cell death following AMG 232 and radiation treatment.
The markedly increased antitumor capacity of AMG 232 and radiation observed in xenograft studies suggest that factors involved in the tumor-stromal interaction, such as angiogenesis, may influence radiation response in vivo. We found that vascular density was significantly reduced in tumors receiving combined treatment of AMG 232 and radiation (Supplementary Fig. 6 ). Although AMG 232 exhibits a 40-fold lower affinity for mouse MDM2 than for human MDM2 in biochemical studies, the decrease of vasculature observed in tumor xenografts likely reflects the decreased tumor growth and tumor-release of angiogenic factors, such as vascular endothelial growth factor (VEGF). MDM2 has shown to be a positive activator of VEGF, and MDM2 inhibitors block VEGF-mediated tumor angiogenesis (35) . Our findings reveal the potential anti-angiogenic capacity of AMG 232 that may contribute to the augmentation of radiation response observed in xenograft studies. A detailed investigation is underway to examine temporal changes of the tumor microenvironment following AMG 232 treatment, including hypoxia and vascular normalization, representing two important factors involved in regulating tumor response to radiation (36, 37 
Previous studies have shown a p53-independent impact of MDM2 inhibitors in tumor cells without functional p53. Using p53-null HCT116 (-/-) and PC3 cells, Lau et al found that treatment with Nutlin-3 at 10~40 μM suppressed cell growth and increased apoptosis by inhibiting the interaction of MDM2 and p73, a p53 isoform (38) . Later, a p53-independent role of Nutlin-3 in radiation-induced DNA damage response was also reported (39, 40) . Although AMG 232 did not inhibit proliferation of H1299 at 10 μM as shown in Fig. 1A , we found that AMG 232 could effectively inhibit tumor growth at a concentrations above 10 μM in cells without wt p53, including H1299, SCC1 and SCC1483 (Supplementary Fig. 7A) . Interestingly, the p53-independent anti-proliferation effect of AMG 232 seemingly had no reliance on MAPK and AKT proliferation/survival signaling, but rather, on cell cycle progression pathway via Rb and FoxM1 as shown in Supplementary Fig. 7B . FoxM1 is of great interest, as it was also significantly reduced following combined AMG 232/radiation treatment in cells with functional p53 (Fig. 3) . Moreover, it has been shown recently that suppression of FoxM1 sensitized cancer 
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